# US 2012/0220492 A1 · Viral Vectors with Improved Properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0220492 A1
- Document ID: US20120220492A1
- Status: Published application
- Kind: A1
- Application number: 13/247,860
- Filed: 2011-09-28
- Published: 2012-08-30
- Earliest claimed: 2003-05-23
- Assignees: Mount Sinai School of Medicine of New York University
- Inventors: Thomas Weber; Laure Gigout
- Web page: https://patentgrep.com/patent/US20120220492A1

## CPC

- C12N 15/86: Viral vectors
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2750/14123: Virus like particles [VLP]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2810/40: Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N 2810/405: Vectors comprising RGD peptide
- C12N 2810/60: from viruses
- C12N 2810/6072: negative strand RNA viruses
- C12N 2810/80: from vertebrates
- C12N 2810/85: mammalian
- C12N 2810/851: from growth factors; from growth regulators
- C12N 2810/854: from hormones
- C12N 2810/859: from immunoglobulins
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2840/44: being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods to improve the tropism or other features of a virus are disclosed. Such methods can be used to prepare, e.g., DNA or plasmid libraries of variants of a gene encoding a viral capsid or envelope protein having a randomly inserted restriction site, libraries of viral clones with such variant genes with a randomly inserted restriction site or polypeptide sequence targeting a receptor expressed by a specific type of mammalian cells. Described are also methods to prepare mosaic viruses, i.e., viral particles wherein copies of one or more capsid or envelope proteins originate from different sources. These methods can be used to prepare mosaic viruses of a specific mixture of wild-type and mutant proteins, or of different types of mutant proteins.

## Claims

### Claim 1

A DNA library comprising variants of a gene encoding viral capsid or envelope protein, wherein each variant contains a randomly inserted restriction site.

### Claim 2 (depends on 1)

The library of claim 1 comprising each possible insertion in a variant gene.

### Claim 3 (depends on 1)

The library of claim 1, wherein the DNA library is a plasmid DNA library.

### Claim 4 (depends on 1)

The library of claim 1, wherein the gene encodes a parvovirus capsid protein.

### Claim 5 (depends on 1)

The library of claim 1, wherein the gene encodes an AAV capsid protein of any AAV serotype.

### Claim 6 (depends on 5)

The library of claim 5, wherein the capsid protein is VP1 comprising the amino acid sequence of SEQ ID NO:1.

### Claim 7 (depends on 5)

The library of claim 5, wherein the capsid protein is VP2 comprising the amino acid sequence of SEQ ID NO:2.

### Claim 8 (depends on 5)

The library of claim 5, wherein the capsid protein is VP3 having the amino acid sequence of SEQ ID NO:3.

### Claim 9 (depends on 1)

The library of claim 1, wherein cutting with a restriction enzyme specific for the restriction site produces blunt ends.

### Claim 10 (depends on 1)

The library of claim 1, wherein cutting with a restriction enzyme specific for the restriction site produces overhanging ends.

### Claim 11 (depends on 10)

The library of claim 10, wherein the restriction site is flanked with sequences encoding a linker.

### Claim 12 (depends on 11)

The library of claim 11, wherein the linker comprises a cysteine residue to promote the formation of a disulfide bond between the flanking linkers.

### Claim 13

A library of virus clones, wherein each clone contains a variant of a gene encoding a viral envelope or capsid protein, wherein each variant contains a randomly inserted restriction site.

### Claim 14 (depends on 13)

The library of claim 13 wherein the restriction site is flanked by sequences encoding a linker.

### Claim 15 (depends on 14)

The library of claim 14 wherein the linker comprises a cysteine residue to promote the formation of a disulfide bond between the flanking linkers.

### Claim 16 (depends on 13)

The library of claim 13 comprising each possible insertion in a variant gene.

### Claim 17

A library of virus clones, wherein each clone contains a variant of a gene encoding a viral envelope or capsid protein, wherein each variant contains a randomly inserted nucleotide sequence encoding a polypeptide sequence.

### Claim 18 (depends on 17)

The library of claim 17, wherein the inserted polypeptide sequence is a targeting sequence.

### Claim 19 (depends on 17)

The library of claim 17 comprising each possible insertion in a variant gene.

### Claim 20

A library of infectious viral particles, wherein each viral particle contains a variant of a gene encoding a viral envelope or capsid protein, wherein each variant contains a randomly inserted polypeptide sequence.

### Claim 21 (depends on 20)

The library of claim 20, wherein the inserted polypeptide sequence is a targeting sequence.

### Claim 22 (depends on 20)

The library of claim 20, wherein each viral particle further contains at least one other variant capsid or envelope protein or at least one other wildtype capsid or envelope protein.

### Claim 23 (depends on 22)

The library of claim 22, wherein the capsid or envelope proteins are from the same virus.

### Claim 24 (depends on 22)

The library of claim 22, wherein the capsid or envelope proteins are from at least two different viruses.

### Claim 25 (depends on 22)

The library of claim 22, wherein each viral particle contains variant capsid or envelope proteins.

### Claim 26 (depends on 22)

The library of claim 22, wherein the targeting polypeptide is a ligand to a receptor expressed by a mammalian cell.

### Claim 27 (depends on 22)

The library of claim 22, wherein the viral particle is a parvovirus.

### Claim 28 (depends on 27)

The library of claim 27, wherein the viral particle is an AAV of any serotype.

### Claim 29

A method of preparing a plasmid library comprising a viral gene with a randomly inserted restriction site, which method comprises:
(a) preparing multiple copies of a first plasmid comprising a first selection marker and a viral gene encoding a viral protein;
(b) preparing multiple copies of a second plasmid comprising a second selection marker flanked by transposon sequences, wherein each transposon sequence comprises a restriction site;
(c) preparing a first plasmid library by contacting each copy of the first plasmid with a copy of the second plasmid in the presence of a transposase; and
(d) selecting a first set of plasmids from the first library that comprises both the first and the second selection markers.

### Claim 30 (depends on 29)

The method of claim 29 wherein the transposon sequences are Tn7 sequences and the transposase is Tn7-transposase.

### Claim 31 (depends on 29)

A method of preparing a library of viral clones, which method comprises transferring each viral gene prepared according to claim 29 into a virus clone, thereby generating a library of viral clones.

### Claim 32 (depends on 29)

A method of preparing a library of viral clones comprising a heterologous polypeptide sequence randomly inserted in a viral gene, which method comprises contacting each member of the library of claim 29 with a restriction endonuclease specific for the restriction site, and ligating a nucleotide sequence encoding a heterologous polypeptide sequence into the plasmid at the restriction site.

### Claim 33 (depends on 32)

The method according to claim 32 wherein the viral gene is a capsid gene or an envelope gene.

### Claim 34 (depends on 31)

A method of preparing a library of pseudotyped viral particles comprising a variant of a capsid gene or envelope gene, which method comprises expressing the library of viral clones of claim 31 in a host cell transfected with a construct that overexpresses a wildtype capsid protein or envelope protein.

### Claim 35 (depends on 34)

The method of claim 34, wherein the virus is a parvovirus.

### Claim 36 (depends on 35)

The method of claim 35, wherein the parvovirus is an AAV virus of any serotype, the capsid gene is an AAV capsid gene, and the host cell is infected with a helper virus.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the host cell is a HEK 293 cell.

### Claim 38 (depends on 36)

The method according to claim 36, wherein the helper virus is an adenovirus.

### Claim 39 (depends on 36)

The method according to claim 36, wherein the helper virus is a herpes virus.

### Claim 40 (depends on 34)

The method according to claim 34, wherein helper functions are provided by a plasmid.

### Claim 41 (depends on 36)

The method of claim 36, wherein the AAV capsid gene encodes an AAV VP1 capsid protein comprising the amino acid sequence of SEQ ID NO:1.

### Claim 42 (depends on 36)

The method of claim 36, wherein the AAV capsid gene encodes an AAV VP2 capsid protein comprising the amino acid sequence of SEQ ID NO:2.

### Claim 43 (depends on 36)

The method of claim 36, wherein the AAV capsid gene encodes an AAV VP3 capsid protein having the amino acid sequence of SEQ ID NO:3.

### Claim 44 (depends on 34)

A method of selecting a virus comprising a variant of a first capsid or envelope protein that alters tropism of the virus for a target cell, which method comprises:
(a) infecting host cells with the pseudotyped viral particles of claim 34;
(b) contacting target cells with viral particles produced from the infected cells of §tep (a) at a multiplicity of infection of less than 1; and
(c) detecting successful infection of the target cells,
wherein successful infection indicates that the tropism of the virus is altered such that it infects the target cell.

### Claim 45 (depends on 44)

The method according to claim 44 wherein infection of cells normally infected by the virus is not successful.

### Claim 46 (depends on 44)

The method according to claim 44 wherein the host cells in step (a) express a second capsid protein or envelope protein whereby the viral particles contain a mosaic capsid or envelope.

### Claim 47 (depends on 21)

The method according to claim 21, wherein the peptide is a member of the group consisting of the HA-epitope, the FLAG-epitope, the serpin-ligand, 4C-RGD, L14, LH, LyP-1, Z34C, VEGF, the c-kit ligand, scFv-ACK2 and scFv-ACK4.

### Claim 48

A host cell for expressing a recombinant replication-defective virus, which host cell comprises a first construct encoding a first capsid or envelope protein-encoding gene, a second construct encoding a second capsid or envelope protein-encoding gene which is a variant comprising a targeting polypeptide sequence, and a construct comprising a replication-defective recombinant viral genome comprising packaging sequences and a heterologous gene for a protein of interest.

### Claim 49 (depends on 48)

The host cell of claim 48, wherein the first capsid or envelope protein-encoding gene is a wildtype gene.

### Claim 50 (depends on 48)

The host cell of claim 48, wherein a ratio of the first construct to the second construct is in proportion to a desired ratio of the proteins in a mosaic viral particle.

### Claim 51 (depends on 48)

The host cell of claim 48, wherein the virus is a parvovirus and the host cell is infected with a helper virus.

### Claim 52 (depends on 51)

The host cell of claim 51, wherein the virus is an AAV of any serotype.

### Claim 53 (depends on 51)

The host cell of claim 51, wherein the helper virus is an adenovirus.

### Claim 54 (depends on 51)

The host cell of claim 51, wherein the helper virus is a herpes virus.

### Claim 55 (depends on 48)

The host cell of claim 48, wherein helper functions are provided by a plasmid.

### Claim 56

A replication-defective viral vector comprising a capsid or envelope comprising a first capsid or envelope protein, a second capsid or envelope protein that is a variant comprising a targeting polypeptide sequence, and a replication-defective recombinant viral genome comprising packaging sequences and a heterologous gene encoding a protein of interest.

### Claim 57

A method of producing a mosaic replication-defective viral vector, which method comprises:
(a) co-transfecting a host cell with a first construct comprising a first gene encoding a first capsid or envelope protein, a second construct comprising a second gene encoding a second capsid or envelope protein, which second capsid or envelope protein is a variant comprising a targeting polypeptide sequence, and a third construct comprising a replication-defective recombinant viral genome comprising packaging sequences and a heterologous gene encoding a protein of interest; and
(b) culturing the host cell under conditions that permit generation of recombinant viral particles comprising a mosaic capsid or envelope.

### Claim 58 (depends on 57)

The method of claim 57, wherein the first and second constructs are present in a ratio to provide for incorporation of a desired ratio of wild-type to variant capsid or envelope protein in a mosaic replication-defective viral vector produced in the host cell.

### Claim 59 (depends on 58)

The method of claim 58, wherein the virus is a parvoviurs.

### Claim 60 (depends on 59)

The method of claim 59, wherein the virus is an AAV of any serotype.

### Claim 61

An AVV mosaic viral vector comprising a gene encoding a protein of interest and further comprising a capsid protein into which the IgG binding domain of Protein A is inserted, wherein said capsid comprises up to about 50% mutant capsid protein.

### Claim 62 (depends on 61)

The AAV mosaic viral vector of claim 61, wherein said capsid protein comprises between about 10% and about 25% mutant capsid protein.

### Claim 63 (depends on 61)

A method for transducing a cell with a protein of interest comprising contacting said cell with an antibody directed against a surface protein of said cell and the AAV viral vector of claim 61.

### Claim 64 (depends on 62)

A method for transducing a cell with a protein of interest comprising contacting said cell with an antibody directed against a surface protein of said cell and the AAV viral vector of claim 62.
